Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Merck QuÃmica Argentina S.A.I.C." found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Merck QuÃmica Argentina S.A.I.C. for you to read. Along with our medical data and news we also list Merck QuÃmica Argentina S.A.I.C. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Merck QuÃmica Argentina S.A.I.C. Companies for you to search.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Company will share three presentations, including in the late breaking session, at the 23rd International Congress of the World Muscle Society, being held October 2 – 6, 2018, at the Intercontinental Hotel in Mendoza, Argentina. Presen...
Pifeltro and Delstrigo have been backed for approval by the CHMP but how well they will fare on the market...
The positive opinion was based on findings from two pivotal, randomized, multicenter, double-blind, active controlled Phase 3 trials.Contributed Author: Merck
Rivals look to broaden coverage across strains
Daiichi Sankyo and a subsidiary of Merck, known as MSD outside North America, agreed to work together to develop the former's -More-
Belén Merck Navarro, Medicine professor at Valencia and Castellón's CEU UCH university is the only Spaniard among the 17 surgeons from 11 different countries that specialize in breast cancer who took part in a clinical trial on the usefulness of 3D images to evaluate the aesthetic results of conservative surgery in breast cancer
Den Herbst könnte man auch als das Weihnachten der Anleger bezeichnen. In aller Regel ist das die beste Jahreszeit für hochqualitative Schnäppchen. Auch dieses Jahr gibt es wieder genügend Auswahl ...
EMERYVILLE, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today that for $15.0 million, it has acquired from Agenus (NASDAQ: AGEN) a partial interest position in the rights to potential milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte under their collaborations with Agenus. ...
Daiichi Sankyo Company has signed a clinical trial collaboration agreement with a Merck subsidiary to conduct a Phase lb trial...Read More... The post Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201 appeared first on Drug Development Technology.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing authorization for two HIV-1 medicines: DELSTRIGO™, a once-daily fixed-dose combination tablet of dorav...
NANJING, China, Sept. 20, 2018 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (SZSE: 300725), a global leader in providing innovative chemistry products and services throughout the pharmaceutical R&D process, recently announced the appointment of Dr. Shijie Zhang as Chief Technology Officer. Shijie joins the company from Agios Pharmaceuticals, Inc., where he was Director of Pro...
Merck will halve the price of its Keytruda cancer drug for its China launch, following a similar move by Bristol-Myers Squibb.
Dateline City: KENILWORTH, N.J. Report Illustrates How Merck Creates Sustainable Value for Business and Society KENILWORTH, N.J., Sept. 20, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today issued its 2017/2018 global Corporate Responsibilit
A damning report by Oxfam claims that pharma giants are ‘depriving’ developing countries of millions of dollars' worth of tax money annually. Oxfam’s report, Prescription for Poverty, slammed Johnson & Johnson, Pfizer, Merck Sharp & Dohme ...
Merck's single-pill combination drug consisting of doravirine, lamivudine and tenofovir disoproxil fumarate was found to be s -More-
The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites events in Africa, startups can find their perfect fit and connect to the global network for collaboration. Are you ready to partner with Merck?
Collaboration Seeks to Develop PCR-produced Linear DNA as a Safer Expression Vector for Vaccines Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned
Company progresses development of tri-specific IO therapeutic ND021 ND021 is designed to improve the risk-benefit profile over conventional IO combination therapies Numab Therapeutics AG, a biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer, today announced it appointed Dr. Ignacio Javi...
Technavio has announced their latest drug pipeline analysis report on nosocomial pneumonia. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of nosocomial
Merck & Co. to launch Keytruda in China at half of US price: report https://www.firstwordpharma.com/node/1592134 $MRK
-- Late Breaking Presentation of Data Supporting MRI T2 as a Potential Marker of Clinical Outcome in Duchenne – -- Presentations on MoveDMD Clinical Results and Polaris DMD Phase 3 Design – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announce
ICON’s CEO Steve Cutler talks candidly about the impact of biotech funding, disruptive tech providers, and the constant pressure of...
Source: Streetwise Reports 09/19/2018 A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner.In a Sept. 11 research note, Mackie Research Capital analyst Andre Uddin reported that IMV Inc. (IMV:TSX; IMMVD:OTCQX) is again collaborating with Merck, this time evaluating its DPX-Survivac with Mer...
Science Exchange, the world’s leading marketplace for outsourced R&D™, today announced a strategic partnership with Clora, a technology platform that precisely matches
Hemispherx Biopharma (NYSE:HEB) announced today regulatory inspection and clearance for distribution of the Company’s second commercial scale lot of Ampligen (rintatolimod), which is slated for multiple uses including product launch in Argentina, where Ampligen is approved for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), ME/CFS expanded access program (EAP) in t...